Improvement of the HIV fusion inhibitor C34 activity by membrane anchoring and enhanced exposure

被引：0
|
作者：
Augusto, M. T. [1 ]
Hollmann, A. [1 ]
Castanho, M. A. R. B. [1 ]
Pessi, A. [2 ]
Santos, N. C. [1 ]
机构：
[1] Univ Lisbon, Fac Med, Inst Med Mol, P-1699 Lisbon, Portugal
[2] PeptiPharma, Rome, Italy
来源：
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS | 2013年 / 42卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [41] Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide
    Yao, Xue
    Chong, Huihui
    Zhang, Chao
    Waltersperger, Sandro
    Wang, Meitian
    Cui, Sheng
    He, Yuxian
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (09) : 6788 - 6796
  • [42] Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay
    Pontow, Suzanne
    Harmon, Brooke
    Campbell, Nancy
    Ratner, Lee
    VIROLOGY, 2007, 368 (01) : 1 - 6
  • [43] Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor
    Liu, Lihong
    Wen, Michael
    Zhu, Qianqian
    Kimata, Jason T.
    Zhou, Paul
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2016, 11 (03) : 601 - 610
  • [44] Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor
    Lihong Liu
    Michael Wen
    Qianqian Zhu
    Jason T. Kimata
    Paul Zhou
    Journal of Neuroimmune Pharmacology, 2016, 11 : 601 - 610
  • [45] Heterologous Src Homology 4 Domains Support Membrane Anchoring and Biological Activity of HIV-1 Nef
    Geist, Miriam M.
    Pan, Xiaoyu
    Bender, Silke
    Bartenschlager, Ralf
    Nickel, Walter
    Fackler, Oliver T.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (20) : 14030 - 14044
  • [46] A Synthetic C34 Trimer of HIV-1 gp41 Shows Significant Increase in Inhibition Potency (vol 7, pg 205, 2012)
    Nomura, W.
    Hashimoto, C.
    Ohya, A.
    Miyauchi, K.
    Urano, E.
    Tanaka, T.
    Narumi, T.
    Nakahara, T.
    Komano, J. A.
    Yamamoto, N.
    Tamamura, H.
    CHEMMEDCHEM, 2012, 7 (04) : 546 - 546
  • [47] Evolution of HIV-1 Resistance to the Fusion Inhibitor C34-CXCR4 and Potential Fitness Costs in Consideration of a Phase 1 Clinical Trial
    Leslie, George J.
    Haggarty, Beth
    Romano, Josephine
    Jordon, Andrea P. O.
    Wang, Jianbin
    Richardson, Max W.
    Riley, James L.
    Holmes, Michael C.
    Tebas, Pablo
    Hoxie, James
    MOLECULAR THERAPY, 2017, 25 (05) : 303 - 303
  • [48] The role of blood cell membrane lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide
    Matos, Pedro M.
    Freitas, Teresa
    Castanho, Miguel A. R. B.
    Santos, Nuno C.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 403 (3-4) : 270 - 274
  • [49] Efficient ER Fusion Requires a Dimerization and a C-Terminal Tail Mediated Membrane Anchoring of RHD3
    Sun, Jiaqi
    Zheng, Huanquan
    PLANT PHYSIOLOGY, 2018, 176 (01) : 406 - 417
  • [50] Studies on the spectral characteristics of efficient HIV-1 fusion inhibitor C22
    Shi Jun
    He Jiao-juan
    Wang Shi-long
    Sun Xiao-yu
    Chen Qing-yu
    SPECTROSCOPY AND SPECTRAL ANALYSIS, 2008, 28 (08) : 1862 - 1865
12345